Juvista
Trial failures threaten UK biotech
February 18, 2011Research and Development AML, AS1411, AS1413, Antisoma, Juvista, Renovo, UK biotech, acute myeloid leukaemia, anti-scarring, biotech
A number of late stage failures from British biotech firms have left a looming question mark over the future of …
